Reaching people who use drugs with sexual and reproductive healthcare through syringe services programs: potential promise and missed opportunities.

Autor: Scheidell JD; Department of Health Sciences, College of Health Professions and Sciences, University of Central Florida, Orlando, FL, USA. Joy.Scheidell@ucf.edu.; Center for Drug Use and HIV/HCV Research, School of Global Public Health, New York University, New York, NY, USA. Joy.Scheidell@ucf.edu., Chueng T; Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA., Ciraldo K; Department of Obstetrics, Gynecology, and Reproductive Sciences, Department of Family Medicine and Community Health, University of Miami, Miller School of Medicine, Miami, FL, USA., Hervera B; Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA., Dakoulas S; Department of Health Sciences, College of Health Professions and Sciences, University of Central Florida, Orlando, FL, USA., Mahachi M; Department of Social and Behavioral Sciences, School of Global Public Health, New York University, New York, NY, USA., Bennett AS; Center for Drug Use and HIV/HCV Research, School of Global Public Health, New York University, New York, NY, USA.; Department of Social and Behavioral Sciences, School of Global Public Health, New York University, New York, NY, USA., Elliott LC; Center for Drug Use and HIV/HCV Research, School of Global Public Health, New York University, New York, NY, USA.; Department of Social and Behavioral Sciences, School of Global Public Health, New York University, New York, NY, USA.
Jazyk: angličtina
Zdroj: Harm reduction journal [Harm Reduct J] 2024 Nov 14; Vol. 21 (1), pp. 198. Date of Electronic Publication: 2024 Nov 14.
DOI: 10.1186/s12954-024-01116-5
Abstrakt: Background: People who use drugs are at elevated sexual and reproductive health risk but experience barriers to services. Syringe services programs (SSP) are an important venue to provide integrated health services. Few studies have examined SSP use within intersecting gender, racial, and ethnic groups, including by injection drug use (IDU), and differences in sexual and reproductive health among these groups.
Methods: Within a cohort study among people who use unprescribed opioids in New York City, we conducted a nested cross-sectional study from November 2021-August 2022 assessing sexual health with a survey (n = 120). The parent study measured baseline characteristics, and the cross-sectional study survey measured self-reported past-year SSP use and sexual and reproductive health. We estimated SSP use within gender, racial, and ethnic groups by IDU, and the prevalence of sexual and reproductive health outcomes by gender, race, ethnicity, and SSP use.
Results: Among men (n = 61) and women (n = 54), SSP use was disproportionately low among Black participants irrespective of IDU. Women reporting SSP use had a higher prevalence of multiple, new, sex trade, and/or casual sex partners, history of STI symptoms, and lack of effective STI prevention, although women who did not use SSP had non-negligible levels of risk with variation between racial and ethnic groups. Among men, sexual and reproductive health varied across racial and ethnic groups but not as clearly by SSP use.
Conclusions: SSP offer opportunity to address elevated STI risk among people who use drugs but may miss certain intersecting gender, race, and ethnic groups.
Competing Interests: Declarations Competing interests The authors declare no competing interests.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje